Endocyte Inc (ECYT)-Pharmaceuticals & Healthcare-Deals and Alliances Profile

Endocyte Inc (ECYT)-Pharmaceuticals & Healthcare-Deals and Alliances Profile


  • Products Id :- GDPH137442D
  • |
  • Pages: 35
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Endocyte Inc (Endocyte) is a developer of new drugs to treat cancer and other serious illnesses. The company's pipeline products include EC1456, EC1788 are used to treat Solid Tumors; EC0652 to treat Prostate Tumors; Folcepri used in treatment of Folate Receptor Positive Tumors; Vynfinit is used in the treatment of non-small cell lung cancer and carboplatin/paclitaxel combination; EC1169 used to treat Prostate Cancer, EC1669 used in the treatment of Inflammation and EC0371 for treatment of Polycystic kidney disease. It operates in Indianapolis and West Lafayette, the US. Endocyte is headquartered in West Lafayette, Indiana, the US.

Endocyte Inc (ECYT)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 4

Endocyte Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5

Endocyte Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6

Endocyte Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7

Endocyte Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8

Endocyte Inc, Medical Devices Deals, 2011 to YTD 2017 9

Endocyte Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10

Endocyte Inc, Pharmaceuticals & Healthcare, Deal Details 11

Partnerships 11

Endocyte Enters into Agreement Seattle Children's Research Institute 11

Merck Enters Into Co-Development Agreement With Endocyte For Cancer Drug 11

Licensing Agreements 13

Endocyte Enters into Licensing Agreement with Nihon Medi-Physics for Etarfolatide 13

Equity Offering 13

Endocyte Completes Public Offering Of Shares For USD108.7 Million 13

Endocyte Completes Underwritten Public Offering Of Common Stock For USD71.2 Million 15

Endocyte Completes IPO For USD86.3 Million 16

Endocyte Inc-Key Competitors 18

Key Employees 19

Locations And Subsidiaries 20

Head Office 20

Other Locations & Subsidiaries 20

Recent Developments 21

Financial Announcements 21

May 10, 2017: Endocyte Reports First Quarter Financial Results and Provides Clinical and Pipeline Update 21

Mar 10, 2017: Endocyte Reports Fourth Quarter and Year End 2016 Financial Results and Provides Clinical and Pipeline Update 23

Nov 09, 2016: Endocyte Reports Third Quarter 2016 Financial Results 25

Aug 04, 2016: Endocyte Reports Second Quarter 2016 Financial Results 27

May 04, 2016: Endocyte Reports First Quarter 2016 Financial Results 29

Mar 02, 2016: Endocyte Reports Fourth Quarter and Year End 2015 Financial Results 30

Corporate Communications 31

Feb 21, 2017: Endocyte Appoints Michael T. Andriole as Chief Financial Officer 31

Jun 20, 2016: Endocyte Appoints Mike Sherman as President and Chief Executive Officer 32

Clinical Trials 33

Apr 20, 2016: Celldex Therapeutics Presents Data Supporting The Preclinical CD40 Antibody Program At The AACR Annual Meeting 2016 33

Apr 19, 2016: Endocyte Announces Promising Preclinical Data for Application of SMDC Technology in CAR T Cell Therapy in Late-Breaking Abstract at American Association for Cancer Research Annual Meeting 2016 34

Appendix 35

Methodology 35

About GlobalData 35

Contact Us 35

Disclaimer 35

List of Figures

Endocyte Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1

Endocyte Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1

Endocyte Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1

Endocyte Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1

Endocyte Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5

Endocyte Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 6

Endocyte Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7

Endocyte Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8

Endocyte Inc, Medical Devices Deals, 2011 to YTD 2017 9

List of Tables

Endocyte Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 1

Endocyte Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5

Endocyte Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6

Endocyte Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7

Endocyte Inc, Deals By Therapy Area, 2011 to YTD 2017 8

Endocyte Inc, Medical Devices Deals, 2011 to YTD 2017 9

Endocyte Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10

Endocyte Enters into Agreement Seattle Children's Research Institute 11

Merck Enters Into Co-Development Agreement With Endocyte For Cancer Drug 11

Endocyte Enters into Licensing Agreement with Nihon Medi-Physics for Etarfolatide 13

Endocyte Completes Public Offering Of Shares For USD108.7 Million 13

Endocyte Completes Underwritten Public Offering Of Common Stock For USD71.2 Million 15

Endocyte Completes IPO For USD86.3 Million 16

Endocyte Inc, Key Competitors 18

Endocyte Inc, Key Employees 19

Endocyte Inc, Other Locations 20

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Endocyte Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license

Single User License
USD 250 INR 16263
Site License
USD 500 INR 32525
Corporate User License
USD 750 INR 48788

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com